TrialClinical pharmacology in drug development2026
Evaluation of clinical cardiac safety of zilurgisertib, an activin receptor-like kinase-2 (ALK2) inhibitor, in healthy participants.
Yan-Ou Yang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.